Use of 5-(2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-n,4-dimethylthiazol-2-amine in combination therapies for cancer
AssigneeAucentra Therapeutics Pty Ltd
InventorsShudong WANG, Jimma L LENJISA
Life of this patent
Estimating the term…
Abstract
A method of treating a proliferative disease or condition in a subject, comprising co-administering 5−(2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-N,4-dimethylthiazol-2-amine (or a pharmaceutically acceptable salt, solvate or prodrug thereof) with an immunotherapeutic agent to the subject. The immunotherapeutic agent may be an immune checkpoint inhibitor such as one capable of inhibiting PD-1, PD-L1/2, CTLA-4, BTLA or Tim-3 and/or one or more of the ligands thereof. Pharmaceutical compositions and kits are also disclosed.
Claims19
A method of treating a proliferative disease or condition in a subject, comprising co-administering 5-(2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-N,4-dimethylthiazol-2-amine (or a pharmaceutically acceptable salt, solvate or prodrug thereof) with an immunotherapeutic agent to the subject.
A pharmaceutical composition for treating a proliferative disease or condition in a subject, comprising 5-(2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-N,4-dimethylthiazol-2-amine (or a pharmaceutically acceptable salt, solvate or prodrug thereof) and an immunotherapeutic agent, optionally in combination with a pharmaceutically acceptable carrier, diluent and/or excipient.
14-19. (canceled)
Dependencies are inferred from the claim text.